Changfeng Bio completes "Tens of Millions of Yuan" Pre-A financing round, building a disruptive "Innovative Biomedical Materials" transformation platform

This round of financing will be used forChangfeng Bio's Continuous Innovation, Clinical Research, and Promotion of the Transformation Platform for Innovative Biomaterials and Its Series of Product Pipelines, further solidifying the company's leading position in the technological platform for the transformation of innovative biomedical materials in multidisciplinary clinical pain point treatments such as medical aesthetics, dentistry, orthopedics, and oncology. Shenzhen Gaohe Capital Holdings Co., Ltd. serves as the long-term exclusive financial advisor for this round and subsequent financing.

Regenerative medical aesthetics stimulates the body's own tissue regeneration through methods such as injections, playing a role in structural remodeling and volume filling to achieve the purpose of anti-aging. With the recent launch of several products,Regenerative medical aesthetic materials have received widespread attention from all sectors of society and the capital market, and the market space for regenerative injectables in mainland China is expected to further expand.According to the latest research data, the market space for regenerative injectables in mainland China's medical aesthetics industry is expected to reach approximately 11.52 billion RMB by 2027, with a compound annual growth rate of about 31.2% during the period from 2025 to 2027.

In April 2025, Guido Kroemer and Carlos López-Otín from Sorbonne University in France published a review article titled "From Geroscience to Precision Geromedicine: Understanding and Managing Aging" in the prestigious international academic journal Cell. This review builds on their previously proposed twelve hallmarks of aging.Added extracellular matrix changes (Extracellular matrix changes; ECM) as the latest hallmark of aging.

Essentially, the extracellular matrix is a dynamic network between cells, comprising different types of collagen, various proteoglycans, elastin, and some adhesive glycoproteins. Collagen or elastin functions in the form of collagen fibers or elastic fibers. Proteoglycans form an amorphous matrix that fills or surrounds the fibers. Various adhesive proteins mediate the interaction and adhesion between fibers, cells, or tissues. This intricate fibrous network, composed of proteins and polysaccharides, forms an essential microenvironment for cell survival. It serves not only as a "support structure" for cells but also as an "information hub" regulating cellular activity.

This review mentions that ECM has a strong impact on mitochondrial homeostasis, cellular senescence, and stem cell exhaustion. Alterations in the ECM can lead to tissue fibrosis, which is both a cause and a consequence of aging. Therefore, changes in the extracellular matrix meet all three stringent criteria and can be considered a new integrative hallmark of aging.

As innovative companies like Changfeng Bio lead the way, regenerative medical aesthetic materials are being brought into the fourth phase of the future market: bioactive regenerative materials, namely ECM (extracellular matrix) materials.Such materials can guide the orderly ingrowth of host cells and tissue regeneration to promote bodily repair, thereby achieving nearly complete natural aesthetic restoration and tissue repair.

Changfeng Bio's independently developed new generation of ECM series materials is one of the few domestic companies that can lead in various materials and technical indicators globally.，Currently, multiple products are in the rapid advancement registration phase.

Changfeng Bio is an innovative biomedical materials platform enterprise focusing on multiple fields such as medical aesthetics, oral, orthopedics, and oncology.The company owns a GMP factory and R&D center of nearly 3,000 square meters in Ningbo, with more than ten cooperative projects with universities and research institutes. It also holds over 20 independent intellectual property rights and is recognized as a technology-based small and medium-sized enterprise and a high-tech enterprise by the state.

Changfeng BioFocus on New Regenerative Materials, providing self-developed next-generation repair and filling materials with higher biocompatibility to address clinical pain points in various scenarios. The company focuses on tissue engineering materials, possesses a full set of core technologies, emphasizes the sourcing and processing of natural polymer raw materials, and has establishedA platform company centered on consumer healthcare, addressing the pain points of serious medical needs, and spanning across medical aesthetics, dentistry, orthopedics, and oncology.。On the raw material side, the company independently controls the upstream supply chain to ensure stable and consistent raw material supply, compliance, and effectiveness; in terms of processing, the company masters the entire set of preliminary processing techniques, ensuring the safety of clinical trials and product supply, in line with national regulatory requirements.

The team has extensive and diverse experience, stemming from the collaboration of top domestic scientists with abundant clinical resources in China. They have been deeply engaged in biomedical materials for decades. The founding team has over a decade of experience working in well-known companies both domestically and internationally, possessing rich expertise in the research and development, registration, clinical studies, quality production, and operation of Class III and Class II medical device products. They also have sales and successful overseas expansion experience in medical aesthetics, orthopedics, and general surgery sectors. The team initially invested independently to build relevant raw material and process platforms.Changfeng Bio has a multi-material, multi-technology platform layout.,An extremely rich product pipeline will lay a solid foundation and strong competitive advantage for the company's future development.

Regarding this round of financing,Changfeng Bio Founder Stated:ECM, as a prominent representative of natural polymer materials, has already achieved surprising efficacy in traditional serious medical treatments, and will undoubtedly lead the next trend in injectable filler materials.; Meanwhile, Changfeng Bio is alsoDevelop a variety ofWorld-leading or original ECM materials, making relentless explorations to address pain points in traditional serious medical fields and applications in anti-aging and regenerative medicine.。

Gu Guan, Partner of Chengshu Investment, commented: "Regenerative biomaterials have always been a key niche segment we focus on, distinguished by high technical barriers, diverse clinical application scenarios, and strong market potential. The Changfeng Bio team has deep expertise in the ECM field accumulated over many years, with substantial experience in core product technology and process development. They demonstrate strong clinical insight and strategic pipeline selection capabilities, and we highly value the company’s differentiated pipelines in medical aesthetics, dental, orthopedics, and oncology. The founding team has a proven track record of multiple successful ventures in healthcare, combining entrepreneurial vision, insight, execution capability, and cohesion. We are confident that they can lead Changfeng Bio to become a leading brand in the innovative biomaterials industry."

Shenzhen Gaohe Capital Holdings Co., Ltd. Managing Partner Liu ShengyuRepresentation: Thank you to Changfeng Bio for recognizing and trusting Gaohe Capital. Gaohe Capital has long been dedicated to the consumer healthcare sector, committed to discovering, supporting, and empowering outstanding enterprises, entrepreneurs, and scientists with fundamental innovative logic and multiple compound capabilities. The more than two years spent alongside Changfeng Bio have been a period of rapid development and swift iteration for the founding team, and even more so, a time when we have borne witness to...Construction of a Disruptive Innovation Regenerative Biomaterials PlatformIn the past two years, we firmly believe that Changfeng Bio will become a leading enterprise in the new generation of regenerative medical materials. We strongly believe that with the relentless efforts of the founding team and the scientific team, as well as the strong support from numerous shareholders, Changfeng Bio will embrace a faster and better development phase. It will also have the opportunity to lead a new wave of development in the regenerative biomaterials market in China and even globally.

Chengshu Investment focuses on growth-stage and early-stage investments in consumer healthcare, medical devices, and life sciences.The management team is a pioneer and builder in China's capital market and healthcare equity investment field, with abundant industry resources and capital market experience. They have a profound understanding of enterprise growth patterns and are committed to continuously empowering the growth of invested companies and creating long-term sustainable value for investors. "Focus, Growth, Long-term" is Chengshu’s investment philosophy. In the early to mid-stage, they identify enterprises with tremendous growth potential and support their critical development phases with capital and resources. They accompany outstanding enterprises and entrepreneurs over the long term and continue to increase investment, becoming co-creators of long-term sustainable value.

Ningbo Yongke AngelIt is a private equity fund management company wholly established by Ningbo Angel Investment Guidance Fund Co., Ltd., relying on the functional positioning and strategic development direction of Ningbo Angel, adopting a market-oriented operation model.Focus on supporting hard-tech enterprises with high technical barriers and great growth potential, especially paying attention to early-stage quality projects.

The company's headquarters is located in Beijing.Through more in-depth industry research and understanding, invest in high-quality listed companies and startups via models such as investment management, investment banking, industrial funds, and M&A funds., and integrate the accumulated industrial resources, financial resources, and industry research to serve all the investors who trust Gaohe Capital and listed companies, pursuing common growth with enterprises and achieving medium- to long-term absolute investment returns.Shenzhen Gaohe Capital Holdings Co., Ltd. is a platform under its umbrella that focuses on in-depth investment, financing, and empowerment within the life sciences and healthcare industries., to address the challenges of innovation and financing within the industry through capital-driven solutions. Committed to discovering the potential of entrepreneurs in the life sciences and healthcare sector, enhancing their skills, stimulating their thinking, and incubating a hundred next-generation leaders in healthcare entrepreneurship over the next decade.